Zaklad i Oddzial Radioterapii

Centrum, Poland

Zaklad i Oddzial Radioterapii

Centrum, Poland
SEARCH FILTERS
Time filter
Source Type

Introduction. In Poland lung cancer has a very poor prognosis and it is the most common cause of cancer deaths. Our aim was to study survival analysis of patients treated for non-small-cell lung cancer (NSCLC) in Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa Spraw Wewnętrznych z Warmińsko-Mazurskim Centrum Onkologii in Olsztyn between 2003 and 2006 (the initial 4 years of Centre activity). Material and methods. The analysis included all patients (801) treated with radiation for NSCLC between 2003 and 2006 (I-IV clinical stages, treated with radical or palliative radiotherapy). Results. Overall 2-year and 5-year survival (OS) of all patients was 19% and 7% (median 7 months). Two-year and five-year OS of patients treated with radical intent was 43% and 18% (median 1 year and 9 months). There was a trend for better prognosis in women (p = 0.075). There was no significant influence of clinical stage, tumour size, histopathology, radiotherapy dose (≤ 60 Gy versus > 60 Gy) or duration of chemoradiotherapy on survival in chemoradiotherapy group (p > 0.05). The only statistically significant factor was lymph node involvement: N0 versus N2 (p = 0.017) and N1 versus N2 (p = 0.008). Conclusions. There was no statistically significant influence of sex, clinical stage, tumour size, histopathology, dose and duration of chemoradiotherapy on OS. The only statistically significant factor was lymph node involvement. © Polskie Towarzystwo Onkologiczne.


Introduction. In Poland, head and neck cancer accounts for some 6% of all cancer cases. The most common cancer in this group is cancer of the larynx. The aim of this study was the estimation of treatment effectiveness of patients treated for laryngeal cancer in the Hospital of the Ministry of Interior with Warmia and Mazury Oncology Center in Olsztyn between 2003 and 2006 (the initial 4 years of the Centre's activity). Material and methods. The analysis included all patients (220) treated with radiation for laryngeal cancer between 2003 and 2006 (I-IV clinical stages, treated with radical and palliative radiotherapy). The Kaplan-Meier method was used to estimate overall survival. Differences in survival of subgroups were evaluated using the log-rank test: but the results have limited value due to retrospective rather than prospective analysis. Results. Overall 2-year and 5-year survival (OS) of all 220 patients was 57% and 43% (median 3 years and 2 months). 2-year and 5-year OS of patients treated with radical intent was 65% and 48% (median of almost 5 years). 2-year and 5-year OS of patients treated with radiotherapy alone and postoperative radiotherapy were respectively 74% and 53%, 63% and 50%. 2-year and 5-year OS of patients in I-II and III-IV clinical stages treated with radiotherapy alone was respectively: 79% vs 45% and 59% vs 18%. (p = 0.004). 2-year and 5-year OS of patients in I-II and III-IV clinical stages treated with postoperative radiotherapy was respectively: 87.5% vs 60% and 87.5% vs 46%. 5-year OS of patients with N0 treated with radiotherapy alone was 57%. None of patients with N1-3 has survived 5 years. 2-year and 5-year OS of patients with N(-) and N(+) treated with postoperative radiotherapy was respectively: 75% vs 50% and 59% vs 40% (p = 0.22). There were no statistically significant differences between the OS of patients treated with standard and hyperfractionated irradiation. Survival of patients treated with radiation for postoperative late relapse was better than the OS of patients treated for postoperative early relapse. Conclusions: Overall survival of patients with less advanced disease and patients with N(-) was significantly longer than the OS of patients with advanced laryngeal cancer. © Polskie Towarzystwo Onkologiczne.


Introduction. Small-cell lung cancer (SCLC) is one of the cancers with the worst prognosis because of its fast growth and early metastases. The aim of this study was the estimation of treatment eff ectiveness of patients treated with small-cell lung cancer in the Hospital of the Ministry of Interior with Warmia and Mazury Oncology Center in Olsztyn between 2003 and 2006 (the initial 4 years of Centre activity). Material and methods. The analysis included all patients (202) treated with radiation for SCLC between 2003 and 2006. Patients in this group (both limited disease-LD and extensive disease-ED) were treated with radical or palliative radiotherapy. The Kaplan-Meier method was used to estimate overall survival. Diff erences in survival of subgroups were evaluated using the log-rank test. Results have limited value due to retrospective analysis. Results. Overall 2- and 5-year overall survival (OS) of all 202 patients was respectively 25% and 10% (median 11 months). 2- and 5-year OS of patients with LD SCLC was respectively 36% and 15% (median 17 months). None of the patients with ED SCLC survived 5 years but one patient survived 2 years (median 3.3 months). 2- and 5-year OS of patients who received concurrent and sequential chemoradiotherapy was 44% vs 31% and 17% vs 16% (p = 0.38). 2- and 5-year OS of patients treated radically, who began radiotherapy with 1 or 2 cycle of chemotherapy, with 3-6 cycle of chemotherapy or after chemotherapy was 48% vs 42% vs 31% and 24% vs 14% vs 16% (diff erences between groups were not statistically signifi cant). There were no diff erences between 2- and 5-year OS of patients treated with radiation administered twice daily and once daily (p = 0.87). Survival of women was better than men. 2- and 5-year OS of women was appropriately 54% and 24% and OS of men was 32% and 13% (p = 0.016). 2- and 5-year OS of patients treated radically, who received PCI was 58% and 18% and OS of patients whodid not receive PCI was 21% and 12% (p = 0.00004). Conclusions. Survival of patients (LD SCLC) who received concurrent chemoradiotherapy was statistically better than patients who received sequential chemoradiotherapy (statistically non-signifi cant). There was a tendency towards better survival if radiotherapy was given with initial cycles of chemotherapy. These results of treatment in the Hospital of the Ministry of Interior with Warmia and Mazury Oncology Center in Olsztyn which were obtained during the initial four years of Centre activity did not diff er from published results of clinical trials. © Polskie Towarzystwo Onkologiczne.


Introduction. Cervical cancer has 7th place according to the frequency of cancer in females in Poland and the results of treatment in Poland are still not satisfactory. The aim of this study was the estimation of treatment effectiveness of patients treated with cervical cancer in the Hospital of the Ministry of Interior with Warmia and Mazury Oncology Center in Olsztyn between 2003 and 2006 (first 4th years of Centre activity). Material and methods. The analysis included all patients (259) treated with radiation for cervical cancer between 2003 and 2006. Patients in that group presented in different stages of clinical advancement (IA-IVB according to FIGO). Patients were treated with radical and palliative radiotherapy, radical chemoradiotherapy, radiotherapy only, and postoperative radiotherapy. The Kaplan-Meier method was used to estimate overall survival. Differences in survival were evaluated using the log-rank test (p < 0.05). Results. Overall 5-year survival of all 259 patients was 46% (median 43.2 months). 5-year survival of patients who received radical radiotherapy was 53% (median 73 months), and for those who received palliative radiotherapy was 10% (median 6.7 months). 5-year survival of patients who received radical chemoradiotherapy was 49% (median 50.8 months). Most of the treated patients were in clinical stage IIB according to FIGO. 5-year survival of patients who received radical chemoradiotherapy in stage IB-IIB and IIIA-IVA was: 55% and 34%. Differences are statistically significant (p = 0.014). Conclusions. Clinical stage at the beginning treatment has a large influence on patient survival. The effectiveness of treatment mainly depends on the stage of clinical advancement. In Poland it is difficult to compare this kind of research with other results because there is still lack of published results. Many publications include the results of international clinical trials, in which patients are selected. This is probably the reason for better overall survival of patients than described in this analysis. © 2013, Polskie Towarzystwo Onkologiczne.

Loading Zaklad i Oddzial Radioterapii collaborators
Loading Zaklad i Oddzial Radioterapii collaborators